Marinus Pharmaceuticals Provides Business Update and Reports Second Quarter 2023 Financial Results
10 August 2023
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that the European Commission (EC) has granted approval of ZTALMY® (ganaxolone) oral suspension for the adjunctive treatment of epileptic seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD) in patients two to 17 years of
31 July 2023
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that the European Commission (EC) has granted approval of ZTALMY® (ganaxolone) oral suspension for the adjunctive treatment of epileptic seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD) in patients two to 17 years of
22 June 2023
Marinus Pharmaceuticals, Inc., a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that the United States Patent and Trademark Office (USPTO) has granted a new method of use patent for intravenous (IV) ganaxolone in the treatment of status epilepticus (SE), expiring in 2040.
26 May 2023
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the approval of ZTALMY® (ganaxolone) oral suspension for the adjunctive treatment of epileptic seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD) in patients two to 17 years of age. ZTALMY may be continued in patients 18 years of age and older.
17 May 2023
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the appointment of Sarah Noonberg, M.D., Ph.D., to its Board of Directors.
Marinus Pharmaceuticals Provides Business Update and Reports First Quarter 2023 Financial Results
11 May 2023
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today reported business highlights and financial results for the first quarter ended March 31, 2023.
24 April 2023
binx health, a healthcare technology and diagnostics company focused on making routine testing convenient, and the Mark Cuban Cost Plus Drug Company, PBC (Cost Plus Drugs) are collaborating to increase access to affordable healthcare and necessary medications for patients across the nation. Together, the companies aim to reduce healthcare disparities and inequities. binx health offers online access to testing to diagnose common conditions such as diabetes, heart disease, and sexually transmitted infections (STIs). Through this collaboration, patients can access testing through binx health’s digital platform, binx everywhere, and receive affordable medication through Cost Plus Drugs online prescription program.
Epic Sciences Announces Medicare Coverage for Breast-Cancer Focused ctDNA Gene Panel
19 April 2023
Epic Sciences, Inc. announced today that the company’s 56-gene ctDNA panel for genomic profiling of metastatic breast cancer is covered by the MolDX program (administered by Palmetto GBA) that provides coverage under the Medicare program for molecular diagnostic tests performed in our region. This panel is a key component of our comprehensive DefineMBC blood biopsy for metastatic breast cancer.
Marinus Pharmaceuticals Appoints Marvin H. Johnson, Jr. to its Board of Directors
18 April 2023
Marinus Pharmaceuticals, Inc., a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the appointment of Marvin H. Johnson, Jr. to its Board of Directors.
binx health Further Expands Commercial Team in Support of Point-of-Care National Rollout
17 April 2023
binx health, a healthcare technology and diagnostics company focused on making routine testing convenient, announces the Company is expanding its commercial organization in response to a growing demand for its FDA-cleared, CLIA-waived, point-of-care (POC) testing platform for chlamydia (CT) and gonorrhea (NG). The binx io is the only molecular POC platform of its kind proven to detect CT and NG in male urine and female vaginal swab samples in about 30 minutes with performance equivalent to the central laboratory.
12 September 2023
Production of one of the world's most sought-after drugs for migraine therapy starts in Moscow
12 July 2023
NovaMedica to localize in Russia one of the most popular anti-migraine drugs in the world
21 March 2023
02 October 2023
The FAS implemented 864 new drug prices in 2022
02 October 2023
Proposed chemical ban would cause EU drug manufacturing to 'grind to a halt,' trade group warns
29 September 2023
Rospotrebnadzor reports: over 18 million people in Russia received the influenza vaccine
29 September 2023